Jefferies Reiterates Buy Rating on Structure Therapeutics (GPCR)

September 8, 2026 9:37 AM

Jefferies analyst Roger Song reiterated a Buy rating and $125.00 price target on Structure Therapeutics (NASDAQ: GPCR).The analyst comments "Bottom ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found